These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 5507168)
21. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
22. World agencies try to stem flood of fake drugs. Surendran A Nat Med; 2004 Feb; 10(2):111. PubMed ID: 14760401 [No Abstract] [Full Text] [Related]
23. Seizures of Canadian drugs rise as Congress, Customs spar. Carreyrou J Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501 [No Abstract] [Full Text] [Related]
24. Pharmacogenomics. Going from genome to pill. Service RF Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283 [No Abstract] [Full Text] [Related]
25. Assuring the quality of the nation's drugs. Interview by William E. Small. Michels D Am Pharm; 1980 Apr; NS20(4):40-2. PubMed ID: 7386377 [No Abstract] [Full Text] [Related]
26. Drug safety: the viewpoint of the pharmaceutical manufacturing industry. Wigle WW Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099 [No Abstract] [Full Text] [Related]
27. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality? Marsh DA; Hoar ME Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245 [TBL] [Abstract][Full Text] [Related]
28. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses. Mahinka SP; Sanzo KM Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000 [No Abstract] [Full Text] [Related]
29. The drug recall dilemma. Provost GP Am J Hosp Pharm; 1966 Oct; 23(10):541. PubMed ID: 5915775 [No Abstract] [Full Text] [Related]
30. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint. Ley HL; Desmond FH Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100 [No Abstract] [Full Text] [Related]
31. New drugs of 1969. De Haen P N Y State J Med; 1970 Mar; 70(6):782-6. PubMed ID: 5264759 [No Abstract] [Full Text] [Related]
32. The relationship between the pharmaceutical industry and government agencies. Johnston RV J Am Vet Med Assoc; 1965 Dec; 147(12):1588-92. PubMed ID: 5884057 [No Abstract] [Full Text] [Related]
33. Planning for change. Hansen DC Bull Parenter Drug Assoc; 1969; 23(1):1-5. PubMed ID: 5765717 [No Abstract] [Full Text] [Related]
34. Progress under the Kefauver-Harris Drug Amendments. Rankin WB Pharmakotherapia; 1964; 2(1):215-22. PubMed ID: 5875717 [No Abstract] [Full Text] [Related]
35. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
36. Pharma's year of trouble and strife. Frantz S Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339 [No Abstract] [Full Text] [Related]